Model‐informed drug development for immuno‐oncology agonistic anti‐GITR antibody GWN323: Dose selection based on MABEL and biologically active dose
Abstract GWN323, an agonistic human anti‐GITR (glucocorticoid‐induced TNFR‐related protein) IgG1 antibody, was studied clinically as an immuno‐oncology therapeutic agent. A model‐based minimum anticipated biological effect level (MABEL) approach integrating in vitro and in vivo data informed dose se...
Enregistré dans:
| Auteurs principaux: | , , , , , , |
|---|---|
| Format: | Livre |
| Publié: |
Wiley,
2022-09-01T00:00:00Z.
|
| Sujets: | |
| Accès en ligne: | Connect to this object online. |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Internet
Connect to this object online.3rd Floor Main Library
| Cote: |
A1234.567 |
|---|---|
| Exemplaire 1 | Disponible |